ABSTRACT: Introduction: The correlation between monofilament testing, symptom surveys, and electrodiagnostic studies for the diagnosis of axonal polyneuropathy has not been well studied. This investigation was done to assess the agreement between these procedures in a non-random sample of volunteers. Methods: The procedures evaluated included electrodiagnostic tests of the sural nerve, monofilament testing of the great toe, a symptom survey, and a body diagram. Kappa coefficients and sensitivity and specificity, using nerve conduction as a ' 'gold standard,' ' were used to determine the agreement between various combinations of procedures. Results: Poor agreement (kappa values À0.12-0.44) and sensitivity (sensitivity <30%) were found for all combinations of symptoms and monofilament results in comparison with sural peak latency and amplitude. Conclusions: Overall, the results demonstrated a low discriminatory power for the screening procedures for identifying persons with impaired sural nerve function. The results highlight the need for further development and evaluation of screening methods for distal neuropathy in population-based studies.
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Quick and accurate screening and clinical diagnoses rely on high sensitivity and specificity for the methods employed. The sensitivity and specificity of the techniques employed significantly affect the outcomes of clinical screening and are also important for epidemiological research of peripheral neuropathy in the lower extremity.
Several tools and procedures, such as electrodiagnostic testing, quantitative sensory tests, physical examination procedures, body diagrams, and symptom questionnaires, have been employed for screening and epidemiological research of peripheral neuropathy. Each of these tools and procedures has strengths and weaknesses. Both electrodiagnostic testing and quantitative sensory tests are highly reproducible and complementary to each other. [2] [3] [4] However, the role of quantitative sensory tests in the diagnosis of distal neuropathy requires further study. 1 The advantage of electrodiagnostic testing is that it provides an objective measure of peripheral nerve function, which clinical psychophysical examinations do not offer. Therefore, to detect peripheral neuropathy in the lower extremities, sural nerve conduction testing is considered to be an appropriate tool. 5 However, electrodiagnostic testing requires specific equipment and training for examiners.
The objective of this study was to assess the agreement between electrodiagnostic testing, monofilament testing, a lower extremity symptom survey, and a body diagram in the identification of possible peripheral neuropathy in the feet. The analysis for the assessment was carried out in a population of dental professionals.
METHODS
Subjects were recruited during the Michigan Dental Association (MDA) annual conventions held in 2009 (n ¼ 232) and 2010 (n ¼ 283). Participants were comprised of a convenience sample of dental professionals who attended the conventions and were recruited for a gene-environment study that investigated the relationship between nerve conduction tests and urinary and hair mercury biomarkers. Each participant signed a written informed consent document approved by the institutional review board of University of Michigan (HUM00027621).
Electrodiagnostic Testing. Nerve conduction tests performed included amplitude, onset latency, and peak latency of the sural nerve in the right ankle. We chose to only present results based on amplitude and peak latency, and not onset latency. The latter is highly correlated with peak latency, and measurement of peak latency tends to have better reliability than onset latency. 4 A TECA Synergy device (Oxford Instruments, Hawthorne, New York) was used to record the amplitude and peak latency after stimulation was applied to the posterior aspect of the right calf, 14 cm proximal to the standard recording electrode placed behind the lateral malleolus in the lower extremity. The temperature of the right midfoot was recorded at the time of measurement. Feet were warmed with electric heating pads if the limb temperature was initially <32
C. The peak latency (milliseconds) was defined as the time required for an electrical stimulus to reach peak deflection from baseline of an action potential waveform. The amplitude (microvolts) was defined as the baseline-to-peak voltage difference of the waveform. We took the best supramaximal stimulation of several trials for our amplitude measurements. All parameters were recorded in accordance with the guidelines outlined by the American Association of Electrodiagnostic Medicine. 6 Self-Administrated Symptom Questionnaire and Body Diagram. Each subject completed a self-administered questionnaire to collect information on demographics and current symptoms of the lower extremities along with pre-existing diseases. If subjects reported any symptoms in their feet in the week prior to the survey, they were asked to report the duration of time they felt numbness and/or tingling in their feet: at <6 weeks; at 6-12 weeks; or at >12 weeks (Sx). Due to small numbers, the duration of symptoms was excluded from subsequent analyses.
Subjects also completed a self-administrated full-body symptom diagram. They were asked to shade areas where numbness, tingling, burning, or pain had occurred more than three times, or had lasted >1 week in the previous 6 months. In this analysis, only areas at or below the right ankle were reviewed and scored independently by two raters for symptoms consistent with neuropathy in the feet. Any discrepancies were reconciled between the two raters through consensus. The results of body diagram symptoms (BDS) were classified into three categories with respect to symptom distribution consistent with neuropathy in the feet, including probable, possible, and unlikely (see Appendix for specific definitions). Symptoms consistent with neuropathy in the feet were defined in different ways using combinations of the body diagram and symptom questionnaire.
Monofilament Testing. The plantar surface of the great toe on the right foot was tested for peripheral sensation using a 5.07-gauge Semmes-Weinstein nylon monofilament (Wound Central, Aurora, Illinois). 7 We chose one monofilament instead of all 20 monofilaments in order to simplify the data collection by minimizing the time spent on each subject and maximizing the sample size of the study. The 5.07-gauge monofilament has been shown to be the best predictor among all 20 monofilaments to determine the loss of protective sensation in the feet among diabetic subjects. 8 The use of a single monofilament resulted in a single outcome (''positive'' or ''negative''). Prior to the test, patients were asked to feel the monofilament on their fingertip. The monofilament was then applied up to three times to the right great toe with sufficient force to bend the filament. Patients were asked to indicate when a touch occurred. The test result was recorded as abnormal if a subject did not indicate a monofilament touch on two consecutive attempts.
Statistical Analyses. Abnormal sural nerve function was defined by two separate criteria used by the University of Michigan Electroneuromyography Laboratory: (1) age-adjusted peak latency >4.1 ms (20-60 years old) or >5 ms (>60 years old); and (2) age-adjusted amplitude 6 lV (20-60 years old) or 5 lV (>60 years old). In addition to age adjustment, the corrected peak latency was defined by adjusting to a standard temperature of 32 C based on the following formula: latency corrected ¼ latency initial À 0.3 ms Á (32-T) C. 9 No temperature adjustment was applied to amplitudes, because, in our data, temperature was not a predictor of the sural amplitude in multivariate linear regression analysis (not shown). Due to missing values (n ¼ 56) for foot temperature, the sample size for peak latency was smaller than that for amplitude.
Because nerve conduction and monofilament tests were conducted only on the right foot, the analyses describe only those results for the right foot. All analyses were performed using SAS software, version 9.2 (SAS Institute, Inc., Cary, North Carolina). Agreement of electrodiagnostic findings with symptoms consistent with neuropathy in the feet and monofilament results, respectively, was assessed by kappa coefficients. Separate kappa coefficients were calculated for all subjects, diabetic subjects, and non-diabetic subjects. Kappa results were interpreted as excellent (>0.75), fair to good (0.40-0.75), or poor (<0.40). 10 Pearson chi-square tests or Fisher exact tests were performed to assess the association of electrodiagnostic findings with symptoms consistent with neuropathy in the feet and monofilament results. Using sural nerve function (peak latency and/or amplitude) as the gold standard, sensitivity and specificity of various combinations of the other tests (body diagram, symptom questionnaire, and monofilament) were calculated. To reflect the clinical relevance of the nerve function as continuous measurements, we also calculated the mean nerve function stratified by various combinations of the clinical tests just noted. Normality tests showed that the distributions were not normal for temperature-and age-adjusted peak latency (Shapiro-Wilk ¼ 0.98; P < 0.0001) and amplitude (Shapiro-Wilk ¼ 0.94; P < 0.0001). The mean amplitude and corrected peak latency were compared between test strata using non-parametric Mann-Whitney tests.
RESULTS
The prevalence of self-reported diabetes was approximately 4% (Table 1) . Diabetic subjects were significantly older and had higher body mass index (BMI) than non-diabetic subjects. The proportions of positive findings for the various symptom criteria (Table 2 ) are shown in Table 3 . Except for peak latency, the proportions of positive findings in the diabetic subjects were higher than those in the non-diabetic subjects. In general, the proportion of abnormal nerve function findings was higher than that of abnormal monofilament results.
The main results are summarized in Table 4 . Overall, kappa values (À0.12-0.44) were mostly poor, sensitivity was low, and specificity was high. Monofilament testing appeared to perform slightly better than symptom surveys among non-diabetic subjects. Not surprisingly, results among diabetic subjects were somewhat better than among non-diabetic subjects. However, the number of diabetic subjects was small, so the confidence intervals tend to be broad, and none of the results achieved statistical significance. Chi-square test statistics and Pvalues showed that significant associations in all subjects occurred only in those combinations having kappa values that were among the highest. In Tables S1-S3 (see Supplementary Material), we also showed kappa values, sensitivity, and specificity for the combinations of monofilament findings and symptom results in comparison with abnormal amplitude or peak latency, abnormal peak latency alone, or abnormal amplitude alone, respectively. We observed similar patterns in the low kappa coefficients, high sensitivity, and low specificity. 
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Pearson chi-square is reported instead because the expected number of subjects in all chi-square 2 Comparisons of means of nerve function between screening test strata were performed using Mann-Whitney tests (see Tables S4 and S5 in Supplementary Material) . Given the small numbers, none of the means differed significantly for either sural amplitude or peak latency among diabetic subjects. Results for all subjects and for non-diabetic subjects were similar. The means of peak latency did not differ significantly for any screening outcome defined purely on the basis of the body diagram with or without symptoms. In contrast, the comparison of mean amplitudes differed significantly in the expected direction for the body diagram and for most combinations of the body diagram with symptoms. The mean peak latency among all subjects with a positive monofilament test (mean ¼ 4.13 ms) was significantly greater than among those with a negative monofilament test (mean ¼ 3.51 ms; P ¼ 0.05). Consistent with the latency results, the mean amplitude among all subjects with a positive monofilament test (mean ¼ 6.71 lV) was significantly lower than among those with a negative monofilament test (mean ¼ 13.12 lV; P < 0.0001). Despite these differences, the overlap of the distributions of nerve test results when stratified by screening test outcome was considerable (see Fig. S1 in Supplementary Material).
DISCUSSION
In this study we assessed the agreement between electrodiagnostic testing results (sural nerve peak latency and amplitude), monofilament findings, and symptoms consistent with neuropathy in the right foot of a non-random convenience sample of dental professionals. Overall, the low kappa coefficients showed poor agreement between electrodiagnostic tests and the other procedures. Kappa coefficients in diabetic subjects were somewhat higher than in non-diabetic subjects.
Using nerve conduction as the gold standard, the sensitivity and specificity of various combinations of the screening tests were mostly low and high, respectively. The results of mean differences in nerve function (see Tables S4 and S5 in Supplementary Material) revealed some significant differences, but the clinical utility of these differences may be limited by the observed considerable overlap of the distributions of ''normal'' and ''abnormal'' screening results. These findings highlight the potential influence of nerve function cut-off values and the potential importance of using nerve function as a continuous versus dichotomous outcome in comparing test procedures. Unlike other clinical procedures that produce binary outcomes, nerve conduction is measured on a continuum. Peripheral neuropathy, defined by measured nerve function, is therefore a continuum. This may have had an impact on the results of poor agreement between the screening procedures, although the direction of such an impact was not clear. However, as shown in Figure S1 (Supplementary Material), there was considerable overlap of the distributions of nerve conduction parameters among those with normal and abnormal screening test results based on monofilaments, body diagrams, or symptoms.
In this study we examined the agreement between different screening tools and procedures for neuropathy in the lower extremity in a nonrandom convenience sample of volunteers. A similar study that investigated such agreement in the upper extremity also reported relatively poor agreement between physical examinations, electrodiagnostic findings, and symptoms consistent with carpal tunnel syndrome. 11 The current results point to a need for further development and evaluation of the methods used to screen for neuropathy in the feet. The low prevalence of positive findings highlights the challenge in developing a screening tool for peripheral neuropathy for use in non-clinical populations, because positive predictive value and negative predictive value are a function of prevalence, and not just sensitivity and specificity. Overall, the results demonstrate a low discriminatory power between the screening procedures for identifying persons with impaired sural nerve function in a non-random convenience sample of volunteers.
